

Coloplast Annual General Meeting

2020/21

Chairman of the Board

Lars Rasmussen

Board of Directors

Other shareholder-elected Board members



Birgitte Nielsen



Carsten Hellmann



Marianne Wiinholt



Jette Nygaard-Andersen

Board of Directors

Employee-elected Board members



Nikolaj Kyhe Gundersen



Roland Vendelbo Pedersen



Thomas Barfod

Executive Leadership Team



Kristian Villumsen
President & CEO



Nicolai Buhl Andersen
Executive Vice
President, Innovation



Anders Lonning-Skovgaard
Executive Vice President &
CFO



Paul Marcun
Executive Vice
President, Growth



Allan Rasmussen
Executive Vice President,
Global Operations



Camilla G. Møhl
Senior Vice President,
People & Culture



Coloplast Annual General Meeting

2020/21



Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors and shareholders
7. Election of members to the Board of Directors
8. Appointment of auditors
9. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors and shareholders
7. Election of members to the Board of Directors
8. Appointment of auditors
9. Any other business

Chairman of the Board

Lars Rasmussen

Solid full-year results despite COVID-19

Organic
growth

7%

EBIT margin*

33%

Return on
invested capital**


45%

* before special items


**before special items and after tax

Brian


COVID-19



We keep our employees safe



We serve our users



*We keep our production
and distribution going*

First year of the 2025 strategy Strive25



Primary strategic initiatives & geographical focus areas



Innovation



Ostomy Care and
Continence Care



Interventional Urology



Digitalization



Sustainability



USA



China



*Making life easier for people living
with a neck stoma, by providing
personalised care and innovative
solutions*



VIDEO – Atos Medical / Joakim

Strive25 – Innovation





Innovation: Growth through clinically differentiated products



Clinical Performance Programme



Biatain® Fiber



Investments in Interventional Urology

Strive25 – Growth



Strive25 – Sustainability



Our mission supports a positive development in society

Our mission

**Making life easier for people
with intimate healthcare needs**

3 GOOD HEALTH
AND WELL-BEING



2025

**Products and
packaging**



2025

**Reduce
emissions**

13 CLIMATE
ACTION



**Responsible
operations**



5 GENDER
EQUALITY



8 DECENT WORK AND
ECONOMIC GROWTH



10 REDUCED
INEQUALITIES

Stina



Strive25 – Unparalleled efficiency





Strive25 – Unparalleled efficiency



Strive25 – Talent, Leadership & Culture



Our Leadership Promise_



VIDEO – Making life easier / Innovation

Key ratios 2020/21

DKK million	2020/21	2019/20	Growth
Net revenue	19,426	18,544	5%
Gross margin	69%	68%	1 pp
Operating profit (EBIT)	6,155*	5,854	5%
Operating margin (EBIT margin)	33%**	32%	1 pp
Net profit for the year	4,825	4,197	15%
ROIC after tax	45%**	46%**	-1 pp
Free cash flow	3,279	3,858	-15%

* After special items

** Before special items

Organic growth rates



Ostomy
Care

6%



Continence
Care

5%



Interventional
Urology

19%




Wound &
Skin Care


8%



Sales performance by region



Operating profit (EBIT)



■ Operating profit (EBIT) before special items (DKK million)

— Operating margin (EBIT, %) before special items






Profit 2020/21

Net profit for the year	DKK 4,825m
Total assets	DKK 15,841m
Equity	DKK 8,168m
Free cash flow for the year	DKK 3,279m
Dividend DKK 19.00 per share	DKK 3,830m
Payout ratio	81%*

* Payout ratio before special items related to mesh litigation.
After special items, the pay-out ratio was 84%

Share price development



Financial guidance for 2021/22 - excluding impact from the Atos Medical acquisition

We expect organic revenue growth of around 7% at constant exchange rates and around 8% in DKK.

We expect a reported EBIT margin of around 32% in Danish kroner.

We expect Capex of around 1.2bn in DKK.

The effective tax rate is expected to be 22-23%.

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors and shareholders
7. Election of members to the Board of Directors
8. Appointment of auditors
9. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors and shareholders
7. Election of members to the Board of Directors
8. Appointment of auditors
9. Any other business

5. Approval of the remuneration of the Board of Directors

The Board of Directors proposes the following remuneration of the Board of Directors for 2021/22:

- ordinary Board members receive a base fee of DKK 450,000;
- the Deputy Chairman of the Board receives a fee of DKK 787,500, i.e. 1.75 times the base fee;
- the Chairman of the Board receives a fee of DKK 1,350,000, i.e. 3 times the base fee.

The Board of Directors proposes a fee of DKK 240,000 for ordinary members of the Audit Committee for 2021/22 and of DKK 430,000 for the Chairman of the Audit Committee, compared with DKK 400,000 in the financial year 2020/21.

The Board of Directors proposes a fee of DKK 150,000 for ordinary members of the Remuneration and Nomination Committee for 2021/22 and of DKK 250,000 for the Chairman of the Remuneration and Nomination Committee.

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors and shareholders
7. Election of members to the Board of Directors
8. Appointment of auditors
9. Any other business

6. Proposals from the Board of Directors

6.1 Update of the Remuneration Policy

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors and shareholders
7. Election of members to the Board of Directors
8. Appointment of auditors
9. Any other business

7. Election of members to the Board of Directors

The Board of Directors proposes re-election of the following members:

- Lars Rasmussen
- Niels Peter Louis-Hansen
- Marianne Wiinholt
- Carsten Hellmann
- Jette Nygaard-Andersen

The Board of Directors proposes election of the following new Board member:

- Annette Bröls

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors and shareholders
7. Election of members to the Board of Directors
8. Appointment of auditors
9. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors and shareholders
7. Election of members to the Board of Directors
8. Appointment of auditors
9. Any other business

Our mission

Making life easier for people
with intimate healthcare needs

Our values

Closeness... to better understand
Passion... to make a difference
Respect and responsibility... to guide us

Our vision

Setting the global standard
for listening and responding